Snibe Launches Lab-based SARS-CoV-2 Antigen Quantitative Detection Kits with CE Mark

Release Date:2021-03-05

Shenzhen, China, 22nd February, 2021-Snibe launches MAGLUMI® SARS-CoV-2 Ag with CE mark, which is a reliable chemiluminescence immunoassay solution for the quantitative detection of nucleocapsid antigens of SARS-CoV-2 from suspected COVID-19 patients. Besides, the SARS-CoV-2 Antigen Test aids to the early detection of SARS-CoV-2 virus from acute COVID-19 infection.


On the envelope of the SARS-CoV-2 virus, there are a number of proteins such as the envelope proteins and spike proteins. Compared to other proteins, nucleocapsid proteins are more conservative. Different from molecular test, which targets the gene segments of virus, antigen test is used to determine whether a patient is infected through detecting the nucleocapsid proteins of the virus particle.


MAGLUMI® SARS-CoV-2 Ag assay runs on all MAGLUMI® Fully-auto chemiluminescence  immunoassay analyzers which are widely available around the world. The SARS-CoV-2 antigen assay can shorten the TAT and simplify operation procedure to improve the efficiency of clinical diagnosis when compared with RT-PCR molecular testing. Therefore it will be more applicable for large-scale testing.

 MAGLUMI® SARS-CoV-2 Ag(CLIA) Kit


Considering that not all locations have the capacity to perform large-scale RT-PCR test for COVID-19 patients, Snibe offers a cost-effective and large-scale detection solution to meet testing needs. The launch of the high-throughput SARS-CoV-2 antigen test will provide a supplement of testing capacity to support medical systems in COVID-19 infection detection.What’s more, in clinical studies, MAGLUMI® SARS-CoV-2 Ag test showed 97.7% sensitivity and 99.6% specificity.


The MAGLUMI® SARS-CoV-2 Ag:
Available as a CE-IVD test for countries accepting the CE-mark.
Aid in early detection of SARS-CoV-2 virus from suspected COVID-19 cases.
Applied to both swabs transported in UTM/VTM and dry nasopharyngeal swab/oropharyngeal swab.
Shorten the TAT and simplify operation procedure to improve the efficiency of clinical diagnosis when compared with RT-PCR molecular testing.
High-throughput quantitative antigen test with CLIA platform.

Sample processing procedure


Snibe is always concerned with global public health and security and ready to help governments cope with public health emergencies. We believe that, with all the efforts from society, we will achieve victory in the fight against SARS-CoV-2 very soon.